Get the latest news, insights, and market updates on FGEN (FibroGen, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
FibroGen Completes Sale of FibroGen China to AstraZeneca for Approximately $220 Million
Total consideration for the sale of FibroGen China to AstraZeneca is approximately $220 million, a $60 million increase from initial guidanceSuccessfully repaid term loan to Morgan Stanley Tactical Value, further simplifying the Company’s capital structurePhase 2 monotherapy trial of FG-3246 in metastatic castration-resistant prostate cancer (mCRPC) remains on track to begin in 3Q 2025Cash runway extended into 2028 SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) t Sep 2, 2025 - $FGEN
FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference
SAN FRANCISCO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Company will be attending and presenting at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025, in New York, NY. Thane Wettig, Chief Executive Officer of FibroGen, will deliver a company presentation on Tuesday, September 9 at 12:00 PM ET at the Lotte New York Palace Hotel. A live webcast of the presentation will be available here. FibroGen’s managemen Aug 27, 2025 - $FGEN
FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation
Sale of FibroGen China remains on track to close in 3Q 2025 SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the China State Administration for Market Regulation approved the sale of FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited, pursuant to the Share Purchase Agreement, dated February 20, 2025. The closing of the transaction remains subject to other contractual closing conditions and deliverables and remains on track t Aug 18, 2025 - $FGEN
FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates
FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock? Aug 11, 2025 - $FGEN
FibroGen: Q2 Earnings Snapshot
SAN FRANCISCO (AP) — FibroGen Inc. FGEN) on Monday reported a loss of $7.6 million in its second quarter. On a per-share basis, the San Francisco-based company said it had a loss of $1.88. Aug 11, 2025 - $FGEN
FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $210 million, a $50 million increase from initial guidance Net cash held in China at closing now estimated to be approximately $125 millionTransaction expected to close in 3Q 2025 Upon close of sale of FibroGen China, cash runway extended into 2028 Initiation of the Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46 in metastatic castration Aug 11, 2025 - $FGEN
FibroGen Announces Positive Type C Meeting with the FDA for Roxadustat in Patients with Anemia Associated with Lower-Risk Myelodysplastic Syndromes
FibroGen has reached agreement with the FDA on important design elements for a pivotal Phase 3 clinical trial for roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high red blood cell (RBC) transfusion burdenCompany intends to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced positive feedback from its Type C meeting with the FDA, supporting Aug 7, 2025 - $FGEN
FibroGen to Report Second Quarter 2025 Financial Results
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce second quarter 2025 financial results on Monday, August 11 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance. Conference Call and Webcast PresentationThe FibroGen management team will host a conference call and webcast presentation to discuss the financ Aug 4, 2025 - $FGEN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple